ADMA Biologics, Inc.   Report issue

For profit Phase 2 Phase 4
Founded: Ramsey NJ United States (2004)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2008
NCT00632463
First Marketed Drug
2004
hepatitis b immune globulin (human) (BayHep B)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

ADMA Biologics, Inc.

Active Ingredients

Marketed Drugs (2)

hepatitis b immune globulin (human) (BayHep B) (2001)

immune globulin (human) (Gamastan) (2012)

Drugs in Phase 4 Trials (1)

immune globulin (human) (Gamastan) (2 trials)

Drugs in Phase 2 Trials (1)

ri-001 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 2)

Immunologic Deficiency Syndromes (Phase 3)

Infections (Phase 2)

Respiratory Tract Infections (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 2